1. Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry
- Author
-
Ronen Gabizon, Rambabu N. Reddi, Nir London, Adi Rogel, Ziv Shulman, Neta Gurwicz, Efrat Resnick, Daniel Zaidman, Kim Goldenberg, Alexander Plotnikov, Haim Barr, and Boddu Venkateswara Rao
- Subjects
biology ,Chemistry ,Leaving group ,Context (language use) ,General Chemistry ,010402 general chemistry ,Ligand (biochemistry) ,01 natural sciences ,Biochemistry ,Combinatorial chemistry ,Article ,Catalysis ,0104 chemical sciences ,Colloid and Surface Chemistry ,Covalent bond ,Electrophile ,biology.protein ,Bruton's tyrosine kinase ,Reactivity (chemistry) ,Cysteine - Abstract
Targeted covalent inhibitors are an important class of drugs and chemical probes. However, relatively few electrophiles meet the criteria for successful covalent inhibitor design. Here we describe α-substituted methacrylamides as a new class of electrophiles suitable for targeted covalent inhibitors. While typically α-substitutions inactivate acrylamides, we show that hetero α-substituted methacrylamides have higher thiol reactivity and undergo a conjugated addition–elimination reaction ultimately releasing the substituent. Their reactivity toward thiols is tunable and correlates with the pKa/pKb of the leaving group. In the context of the BTK inhibitor ibrutinib, these electrophiles showed lower intrinsic thiol reactivity than the unsubstituted ibrutinib acrylamide. This translated to comparable potency in protein labeling, in vitro kinase assays, and functional cellular assays, with improved selectivity. The conjugate addition–elimination reaction upon covalent binding to their target cysteine allows functionalizing α-substituted methacrylamides as turn-on probes. To demonstrate this, we prepared covalent ligand directed release (CoLDR) turn-on fluorescent probes for BTK, EGFR, and K-RasG12C. We further demonstrate a BTK CoLDR chemiluminescent probe that enabled a high-throughput screen for BTK inhibitors. Altogether we show that α-substituted methacrylamides represent a new and versatile addition to the toolbox of targeted covalent inhibitor design.
- Published
- 2021